Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A paper published in Psychotherapy and Psychosomatics (P&P) analyzes the measures that are chosen as outcome in psychiatric trials and questions their clinical validity.
The Authors advocate the use of simpler measures and more ecologically valid designs to answer the central questions on how do we know if one treatment works better than another, and who is going to benefit of such treatments. As highlighted by Arfken and Balon, the use of valid and reliable scales plays an essential role in research. However, the scales commonly used in psychiatry are difficult to understand. This is mainly due to the fact that most measures used in psychiatry do not provide simple and understandable answers for the public. Hence, the need to develop outcomes that are understandable to patients, families and policymakers is impending. Also, efficacious treatments should not be restricted to specialized centers or specialists. The process of identification and treatment or referrals of psychiatric disorders by primary care practitioners should be widely practiced. Instead, primary care practitioners intervene dispensing medications to people with psychiatric disorders, making medications even more widely used. The Authors pointed out that relevant information for patients, families and society, are those related to mortality, functioning, health care utilization and quality of life. Practitioners need this information, as well as, clinical measures that capture clinical signs and symptoms to evaluate the progression and severity of diseases.
More ecologically valid trials, defined as a simple protocol mimicking routine clinical practice and eligibility criteria, and trials of longer duration with mortality as the outcome would provide more reliable information.
Another Look at Outcomes and Outcome Measures in Psychiatry: Cui bono?, Authors: Arfken C.L. Balon R., Psychother Psychosom (2014) DOI:10.1159/000353462
Journal of Psychotherapy and Psychosomatics
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Psychology / Psychiatry category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Journal of Psychotherapy and Psychosomatics. "What is important for a psychiatric patient in a trial." Medical News Today. MediLexicon, Intl., 3 Feb. 2014. Web.
12 Mar. 2014. <http://www.medicalnewstoday.com/releases/272027>
Journal of Psychotherapy and Psychosomatics. (2014, February 3). "What is important for a psychiatric patient in a trial." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/272027.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.